An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib.
Mateo, J Moreno, V Gupta, A Kaye, S Dean, Emma J Middleton, M Friedlander, M Gourley, C Plummer, R Rustin, G
Mateo, J
Moreno, V
Gupta, A
Kaye, S
Dean, Emma J
Middleton, M
Friedlander, M
Gourley, C
Plummer, R
Rustin, G
Citations
Altmetric:
Abstract
Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation.
Description
Date
2016-06
Publisher
Collections
Keywords
Type
Article
Citation
An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. 2016, 11 (3):401-15 Target Oncol